When will the FDA approve Intellia Therapeutics' lonvo-z?

Kalshi Health › FDA & drugs Closes Dec 31, 2027 · $5.9K traded · $3K at stake · prices read 3 h ago

The odds

92%Before October 2027

Before October 202792%
Before 202891%
Before July 202789%

How the odds have moved

Before October 2027: 90% on Oct 20, 92% now.

Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.

Every outcome

Outcome	Chance	Bid	Ask	Pays	Contracts
Before October 2027	92%	91¢	93¢	$1.08	1.1K
Before 2028	91%	89¢	92¢	$1.09	707
Before July 2027	89%	88¢	90¢	$1.11	4.7K

"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".

The news: FDA, Intellia Therapeutics, Lonvoguran Ziclumeran

Search ›

Intellia Therapeutics (NTLA) Stock Could Look Stretched On Phase 3 Trial ProgressYahoo Finance · 3 days agoOver the last 5 years, Intellia's share price has fallen about 91.4%, which puts the spotlight firmly on whether the current valuation is still anchored to its underlying sales. Completion of key Phase 3 trials and preparations for…
Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business UpdatesInvesting News Network (INN) · 5 days agoInvesting News Network Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates - On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date - New lonvo-z patient…
Intellia Therapeutics (NASDAQ:NTLA) Posts Quarterly Earnings ResultsMarkets Daily · 3 days agoPosted by Kim Johansen on Nov 7th, 2026 Shares of NTLA traded up $0.25 during trading hours on Friday, reaching $11.35. 4,402,763 shares of the stock traded hands, compared to its average volume of 5,430,535. The company’s 50-day moving…
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance · 3 days agoCAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today…
Intellia Therapeutics, Inc. (NTLA)Yahoo Finance · 5 days agostock price, news, quote and history Yahoo Finance Singapore Trailing total returns as of 04/11/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
Intellia Therapeutics GAAP EPS of -$0.91 misses by $0.11, revenue of $7.16M misses by $2.61MSeeking Alpha · 5 days agoIntellia Therapeutics Q3 earnings missed on EPS and revenue as collaboration revenue fell. - Intellia Therapeutics press release (NTLA): Q3 GAAP EPS of -$0.91 misses by $0.11. - Revenue of $7.16M (-48.0% Y/Y) misses by $2.61M…
Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in FocusTradingView · 3 days agoIntellia Therapeutics NTLA incurred a third-quarter 2026 loss of 91 cents per share, wider than the Zacks Consensus Estimate of a loss of 82 cents. The loss narrowed 1.1% from 92 cents per share in the year-ago quarter. Intellia’s total…
Intellia: Quiet Q3 Earnings As All Eyes Turn To March 2027 Approval DecisionSeeking Alpha · 3 days agoSeeking Alpha - Intellia Therapeutics approaches a pivotal FDA decision in March 2027 for lonvo-z, potentially the first in vivo CRISPR therapy for hereditary angioedema. - Lonvo-z's Phase 3 data showed ~87% attack reduction and a clean…
Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran Medical Congress PresentationsInvesting News Network (INN) · 7 days agoInvesting News Network Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran Medical Congress Presentations - Presentation at AHA on Nov. 9 to highlight cardiac outcomes following a single dose of nex-z in patients with ATTRv-PN…
Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress PresentationsThe Manila Times · 7 days agoAHA Poster Presentation Details: Type and Session: Moderated Digital Poster - Clinical Science Zone 2 Date and Time: Monday, November 9, 11:13 a.m. CT Presenter: Yousuf Razvi, MBChB BSc, National Amyloidosis Centre, UCL Division of…
Deucrictibant capsule shortens time to symptom relief after hereditary angioedema attackhealiotwo · 8 days agoWhen used as an on-demand treatment for hereditary angioedema attacks, deucrictibant immediate-release led to a shorter time to onset of symptom relief and complete symptom resolution than placebo, according to data published in The…
FDA grants tentative approval to low-cost HIV shotsemafor.com · 5 days agoThe potential rollout of a more affordable injection to help prevent HIV infection lifts hopes for reduced AIDS deaths in Africa. US regulatorsâ approval of a cheaper HIV shot has lifted hopes in some of the worldâs poorest countries…

Related markets

All fda & drugs ›

Health › FDA & drugs

When will Compass Pathways submit a NDA for COMP360 psilocybin? (COMP360 psilocybin - NDA)

98%before December

before December98%▲ 6
before 202798%▲ 6
before April 202798%

Health › FDA & drugs

Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)

14%chance▼ 2

Health › FDA & drugs

Will the FDA approve retatrutide? (retatrutide (LY3437943))

Dec 9, 2027even chance by

Before Jan 1, 20272%▲ 1
Before Jul 1, 202712%▼ 5
Before Jan 1, 202856%

2 more

Before Jul 1, 202885%
Before Jan 1, 202990%

Health › FDA & drugs

When will the FDA reclassify BPC-157 to Category 1?

10%Before 2027

Before 202710%▲ 1

Health › FDA & drugs

FDA decision: Vamikibart by Genentech (on or before July 31, 2027)

64%chance▲ 2

Health › FDA & drugs

When will the FDA approve Compass Pathways' COMP360 Psilocybin? (COMP360 Psilocybin for Treatment-Resistant Depression)

91%Before 2028

Before 202891%
Before October 202788%
Before July 202787%

2 more

Before Mar 1, 202766%
Before Jan 1, 202719%▲ 2

Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Progressives. Prices read from the venues 2 min ago. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.

About this market

VenueKalshi

Settles onU.S. Food and Drug Administration., FDA, Intellia Therapeutics

Trading closesDec 31, 2027 11:59 PM ET

Traded$5.9K (6,562 contracts)

This week$6

At stake$3K

In the news92 headlines today, 815 this week

Followed here sinceOct 19, 2026

The rules

If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jul 1, 2027, then the market resolves to Yes.

The full rules are on the market's page at Kalshi.

Reading the odds

A prediction market trades contracts that pay $1 if something happens. Its price is the market's chance: a contract at 62¢ means traders give it 62%. Each number here is the midpoint between the best bid and offer, or the last trade when they are more than ten cents apart.

For a question with many answers (who wins, which range a number lands in), the chances are scaled to add up to 100%. A price ladder ("above 4.25%, above 4.50% ...") gives a whole distribution: its median is where traders see an even chance either way.

Kalshi is a U.S. exchange regulated by the CFTC; its money is counted in contracts, shown here as dollars at their price. Polymarket counts dollars. ForecastEx is Interactive Brokers' exchange, regulated by the CFTC; its contracts too are shown as dollars at their price. Crypto.com lists its markets on Crypto.com | Derivatives North America, a U.S. exchange regulated by the CFTC; it reports the dollars traded. Where more than one asks the same question, each is shown, never averaged.

Prefer betting odds? Switch to American (+150) or decimal (2.50) odds at the top of the page.

Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Progressives, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Progressives index; prices of stocks, rates and coins from 4Progressives Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions